---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004274"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:05:54.184136+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma expects 2022 Adj. Cash Receipts ~$2.79B, at upper end of guidance; 31% YoY growth

## Summary
- 2022 Adjusted Cash Receipts (non-GAAP) expected ~$2,785-2,790M, towards upper end of $2,750-2,800M guidance; 31% YoY growth.
- 2022 GAAP operating cash flow expected ~$2,140-2,150M.
- Since 2020, announced $10B in transactions; investments expected to add ~$1B to annual Adjusted Cash Receipts in 2025.
- Added royalties on six new therapies in 2022, including Trelegy (respiratory), olpasiran, aficamten, and MK-8189.
- Capital deployment target $10-12B over five years; potential to double to $4-5B annually longer term.

## SEC filing metadata
- accession: 0001193125-23-004274
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312523004274/0001193125-23-004274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312523004274/d446015d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004274
- JSON: https://secwatch.observer/filing/0001193125-23-004274.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004274.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.